Abstract
Osteoarthritis (OA) is a common cause of joint pain and physical disability in the elderly. It is highly associated with local inflammatory reactions and cartilage degradation. Isorhapontigenin (ISO), a natural compound existing in various plants, has shown prominent anti-inflammatory and anti-oxidative properties in several inflammatory diseases. However, the effects of ISO on OA remain to be elucidated. Here, we investigated the effects of ISO on interleukin-1β (IL-1β)-treated rat chondrocytes and cartilage explants. Our results revealed that ISO could suppress the IL-1β-induced elevated levels of nitric oxide (NO), inducible nitric oxide synthase (iNOS), prostaglandin E2 (PGE2), and cyclooxygenase-2 (COX2). Besides, ISO could also inhibit the IL-1β-induced up-regulation of cartilage matrix catabolic enzymes such as matrix metalloproteinases (MMPs) and aggrecanase-2 (ADAMTS5). Moreover, the IL-1β-induced downregulation of collagen II and aggrecan could be reversed by ISO. Furthermore, ISO prevented rat cartilage explant damage induced by IL-1β. Mechanistically, ISO worked partly by suppressing mitogen-activated protein kinase (MAPK)-associated ERK and p38 pathways. Taken together, our study indicated the anti-inflammatory potential of ISO on IL-1β-treated rat chondrocytes, providing a new idea for OA treatment.
Similar content being viewed by others
References
Mathiessen, A., and P.G. Conaghan. 2017. Synovitis in osteoarthritis: current understanding with therapeutic implications. Arthritis Research & Therapy 19 (1): 18.
Aicher, W.K., and B. Rolauffs. 2014. The spatial organisation of joint surface chondrocytes: review of its potential roles in tissue functioning, disease and early, preclinical diagnosis of osteoarthritis. Annals of the Rheumatic Diseases 73 (4): 645–653.
Troeberg, L., and H. Nagase. 2012. Proteases involved in cartilage matrix degradation in osteoarthritis. Biochimica et Biophysica Acta 1824 (1): 133–145.
Glyn-Jones, S., A.J.R. Palmer, R. Agricola, A.J. Price, T.L. Vincent, H. Weinans, and A.J. Carr. 2015. Osteoarthritis. Lancet 386 (9991): 376–387.
Bonnet, C.S., and D.A. Walsh. 2005. Osteoarthritis, angiogenesis and inflammation. Rheumatology (Oxford) 44 (1): 7–16.
Dodge, G.R., and A.R. Poole. 1989. Immunohistochemical detection and immunochemical analysis of type II collagen degradation in human normal, rheumatoid, and osteoarthritic articular cartilages and in explants of bovine articular cartilage cultured with interleukin 1. The Journal of Clinical Investigation 83 (2): 647–661.
Le Maitre, C.L., et al. 2007. Matrix synthesis and degradation in human intervertebral disc degeneration. Biochemical Society Transactions 35 (Pt 4): 652–655.
Goldring, S.R., and M.B. Goldring. 2004. The role of cytokines in cartilage matrix degeneration in osteoarthritis. Clinical Orthopaedics and Related Research (427 Suppl): S27–S36.
Chabane, N., N. Zayed, H. Afif, L. Mfuna-Endam, M. Benderdour, C. Boileau, J. Martel-Pelletier, J.P. Pelletier, N. Duval, and H. Fahmi. 2008. Histone deacetylase inhibitors suppress interleukin-1beta-induced nitric oxide and prostaglandin E2 production in human chondrocytes. Osteoarthritis and Cartilage 16 (10): 1267–1274.
Wang, Q.L., M. Lin, and G.T. Liu. 2001. Antioxidative activity of natural isorhapontigenin. Japanese Journal of Pharmacology 87 (1): 61–66.
Yeo, S.C.M., P.S. Fenwick, P.J. Barnes, H.S. Lin, and L.E. Donnelly. 2017. Isorhapontigenin, a bioavailable dietary polyphenol, suppresses airway epithelial cell inflammation through a corticosteroid-independent mechanism. British Journal of Pharmacology 174 (13): 2043–2059.
Kawakami, S., Y. Kinoshita, H. Maruki-Uchida, K. Yanae, M. Sai, and T. Ito. 2014. Piceatannol and its metabolite, isorhapontigenin, induce SIRT1 expression in THP-1 human monocytic cell line. Nutrients 6 (11): 4794–4804.
Liu, Y., and G. Liu. 2004. Isorhapontigenin and resveratrol suppress oxLDL-induced proliferation and activation of ERK1/2 mitogen-activated protein kinases of bovine aortic smooth muscle cells. Biochemical Pharmacology 67 (4): 777–785.
Oh, J.S., I.A. Cho, K.R. Kang, J.S. You, S.J. Yu, G.J. Lee, Y.S. Seo, C.S. Kim, D.K. Kim, S.G. Kim, Y.W. Seo, H.J. Im, and J.S. Kim. 2016. Biochanin-A antagonizes the interleukin-1beta-induced catabolic inflammation through the modulation of NFkappaB cellular signaling in primary rat chondrocytes. Biochemical and Biophysical Research Communications 477 (4): 723–730.
Chen, P., S. Zhu, Y. Wang, Q. Mu, Y. Wu, Q. Xia, X. Zhang, H. Sun, J. Tao, H. Hu, P. Lu, and H. Ouyang. 2014. The amelioration of cartilage degeneration by ADAMTS-5 inhibitor delivered in a hyaluronic acid hydrogel. Biomaterials 35 (9): 2827–2836.
Wojdasiewicz, P., L.A. Poniatowski, and D. Szukiewicz. 2014. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediators of Inflammation 2014: 561459.
Su, S.C., K. Tanimoto, Y. Tanne, R. Kunimatsu, N. Hirose, T. Mitsuyoshi, Y. Okamoto, and K. Tanne. 2014. Celecoxib exerts protective effects on extracellular matrix metabolism of mandibular condylar chondrocytes under excessive mechanical stress. Osteoarthritis and Cartilage 22 (6): 845–851.
Dragos, D., M. Gilca, L. Gaman, A. Vlad, L. Iosif, I. Stoian, and O. Lupescu. 2017. Phytomedicine in joint disorders. Nutrients 9 (1): 70.
Abbas, A.M. 2016. Cardioprotective effect of resveratrol analogue isorhapontigenin versus omega-3 fatty acids in isoproterenol-induced myocardial infarction in rats. Journal of Physiology and Biochemistry 72 (3): 469–484.
Dai, Y., S.C.M. Yeo, P.J. Barnes, L.E. Donnelly, L.C. Loo, and H.S. Lin. 2018. Pre-clinical pharmacokinetic and metabolomic analyses of isorhapontigenin, a dietary resveratrol derivative. Frontiers in Pharmacology 9: 753.
Roos, E.M., and N.K. Arden. 2016. Strategies for the prevention of knee osteoarthritis. Nature Reviews Rheumatology 12 (2): 92–101.
Attur, M., I. Belitskaya-Lévy, C. Oh, S. Krasnokutsky, J. Greenberg, J. Samuels, S. Smiles, S. Lee, J. Patel, H. al-Mussawir, G. McDaniel, V.B. Kraus, and S.B. Abramson. 2011. Increased interleukin-1beta gene expression in peripheral blood leukocytes is associated with increased pain and predicts risk for progression of symptomatic knee osteoarthritis. Arthritis and Rheumatism 63 (7): 1908–1917.
Wang, P., et al. 2018. Histone deacetylase-4 and histone deacetylase-8 regulate interleukin-1beta-induced cartilage catabolic degradation through MAPK/JNK and ERK pathways. International Journal of Molecular Medicine 41 (4): 2117–2127.
Cao, M., et al. 1997. Nitric oxide inhibits the synthesis of type-II collagen without altering Col2A1 mRNA abundance: prolyl hydroxylase as a possible target. The Biochemical Journal 324 (Pt 1): 305–310.
Takada, K., et al. 2013. Endoplasmic reticulum stress mediates nitric oxide-induced chondrocyte apoptosis. Biomedical Reports 1 (2): 315–319.
Dumond, H., N. Presle, P. Pottie, S. Pacquelet, B. Terlain, P. Netter, A. Gepstein, E. Livne, and J.Y. Jouzeau. 2004. Site specific changes in gene expression and cartilage metabolism during early experimental osteoarthritis. Osteoarthritis and Cartilage 12 (4): 284–295.
Vo, N.V., R.A. Hartman, T. Yurube, L.J. Jacobs, G.A. Sowa, and J.D. Kang. 2013. Expression and regulation of metalloproteinases and their inhibitors in intervertebral disc aging and degeneration. The Spine Journal 13 (3): 331–341.
Saklatvala, J. 2007. Inflammatory signaling in cartilage: MAPK and NF-kappaB pathways in chondrocytes and the use of inhibitors for research into pathogenesis and therapy of osteoarthritis. Current Drug Targets 8 (2): 305–313.
Sondergaard, B.C., N. Schultz, S.H. Madsen, A.C. Bay-Jensen, M. Kassem, and M.A. Karsdal. 2010. MAPKs are essential upstream signaling pathways in proteolytic cartilage degradation—divergence in pathways leading to aggrecanase and MMP-mediated articular cartilage degradation. Osteoarthritis and Cartilage 18 (3): 279–288.
Cargnello, M., and P.P. Roux. 2011. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiology and Molecular Biology Reviews 75 (1): 50–83.
Acknowledgments
This study was supported by the grant from the National Natural Science Foundation of China (no. 51537004) to H.W.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
This study was in strict accordance with the Guidelines of Animal Care and Use Committee for Teaching and Research of Huazhong University of Science and Technology, Wuhan, China.
Conflict of Interest
The authors have no conflict of interest or financial disclosures with this research.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ma, Y., Tu, C., Liu, W. et al. Isorhapontigenin Suppresses Interleukin-1β-Induced Inflammation and Cartilage Matrix Damage in Rat Chondrocytes. Inflammation 42, 2278–2285 (2019). https://doi.org/10.1007/s10753-019-01092-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10753-019-01092-0